Sen. Elizabeth Warren (D-Mass.) is not happy with how the Trump administration handled UnitedHealth Group Inc. (NYSE:UNH)'s $3.3 billion purchase of Amedisys Inc. In a post on X Sunday, she blamed the Department of Justice under President Donald Trump for letting the deal go through, arguing it gives the insurer more power to raise costs and deny care.

Concerns Over UNH's Control Over Patient Care

Warren's argument is straightforward: UnitedHealth already sells insurance, employs doctors, and manages prescriptions. Adding Amedisys, a home health and hospice provider, gives it an even bigger share of patient care. "We need to break up Big Medicine," she said, adding that the DOJ allowed the companies "MORE power to raise costs and deny care."

The senator has been campaigning to break up vertically integrated healthcare companies, which she says raise costs for patients by putting insurance, pharmacy, and care under one roof.

DOJ Sued, Then Settled

The deal didn't sail through without a fight. The DOJ sued to block it in November 2024, then reached a proposed settlement in August 2025 that was approved by the court in December 2025. Under that settlement, UnitedHealth and Amedisys had to sell 164 home health and hospice locations in 19 states, which brought in about $528 million a year. Amedisys also paid a $1.1 million civil penalty for giving regulators inaccurate information during the antitrust review, and a monitor was appointed to oversee the sales.

Bill Would Force Divestitures

Warren isn't just complaining on social media. She co-sponsored the Patients Before Monopolies Act (S. 4509) with Sen. Josh Hawley (R-Mo.). The bill was reintroduced in May after first launching in 2024. It would prohibit PBMs and pharmacies from being under common ownership and require affected companies to divest their pharmacy assets within a year.

Billionaire Mark Cuban has made a similar critique, accusing vertically integrated healthcare companies of exploiting employers' reluctance to change.

Price Action: On Friday, UnitedHealth's shares closed 0.96% lower at $406.97 and lost 0.08% to $406.60 in premarket trading on Monday, according to Yahoo Finance.

MarketDash Edge rankings indicate UnitedHealth's stock has a Momentum score in the 75th percentile and a Growth score in the 19th percentile.